Mobilizing the
Human Immune System
to Combat Disease
HiFiBiO Therapeutics is an emerging multinational company that will soon transform patient care.
Home
Mobilizing the
Latest News
Nov 1, 2021
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301
HFB200301 is a First-In-Class TNFR2 Agonist Antibody for the treatment of DIS™ Defined Solid Tumors CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, and PARIS – November 1, 2021 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for … Continued
Sep 23, 2021
HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern
CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, PARIS – September 23, 2021 – HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and single-cell science, today announced a publication in Science in collaboration with the Coronavirus Immunotherapy Consortium (CoVIC), a global, academic-industry, non-profit research alliance that was established to accelerate discovery, optimization, and delivery of … Continued
Aug 9, 2021
HiFiBiO Strengthens its Senior Leadership Team in Preparation for First-in-Human Studies of Two Lead Immunoncology Programs and a Sustainable Pipeline
(From left to right) Christos Hatzis, PhD, Vice President, Head of Clinical Pharmacogenomics, John Pallante, Vice President, Head of Clinical Operations, and Edward Rocnik, PhD, Executive Director, Head of CMC have joined the company’s senior leadership team. CAMBRIDGE, Mass. – August 9, 2021 – HiFiBiO Therapeutics has onboarded three new senior leaders to help drive … Continued
Nov 1, 2021
HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301
HFB200301 is a First-In-Class TNFR2 Agonist Antibody for the treatment of DIS™ Defined Solid Tumors CAMBRIDGE, MA., HONG KONG, HANGZHOU, SHANGHAI, and PARIS – November 1, 2021 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for … Continued
Unprecedented Discovery and Development Engine
Drug Discovery and Development Expertise
Back
Drug Discovery and Development Expertise
• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients
Transformational Single-Cell Platform
Back
Transformational Single-Cell Platform
• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success
Dynamic and Sustainable Pipeline
Back
Dynamic and Sustainable Pipeline
• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models
Unique Immune Profiling Translational Focus
Back
Unique Immune Profiling Translational Focus
• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action
Open-Innovation Strategy
Back
Open-Innovation Strategy
• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy
• Seasoned leadership team with decades of drug R&D and clinical experience at leading pharmaceutical companies
• Proven track record of delivering multiple clinical and marketed immunotherapies to patients
• Pioneer in ultra-high throughput phenotyping and genotyping single-cell analysis
• Our Drug Intelligent Science (DIS™) approach leverages our proprietary single cell platform to rapidly identify differentiated therapeutic molecules and improve clinical probability of success
• We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types
• Majority of our programs are first-in-class with multiple preclinical candidates demonstrating proof of concept in animal models
• Engagement with the world’s leading clinical immunologists and oncologists to advance a clinical development strategy that better connects biological targets to patient characteristics
• We select indications based on unmet medical needs and our deep understanding of mechanisms of action
• We continue to establish strategic partnerships with both leading pharmaceutical and biotechnology companies as well as academic institutions to accelerate the development of novel R&D technology platforms and therapeutics
• Our collaborations are architected for quality and speed while driven by our scientific strategy